Phase I Study of Farnesyl Transferase Inhibitor (BMS-214662) In Acute Leukemias, Myelodysplastic Syndromes And Chronic Myeloid Leukemia In Blast Phase

Trial Profile

Phase I Study of Farnesyl Transferase Inhibitor (BMS-214662) In Acute Leukemias, Myelodysplastic Syndromes And Chronic Myeloid Leukemia In Blast Phase

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2014

At a glance

  • Drugs BMS 214662 (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Acute promyelocytic leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top